pioneer 5 semaglutide Efficacy and safety of oral by subgroups of patient characteristics in the phase 3 programme Post hoc analysis of SUSTAIN

The British Journal of Dermatology cohort study reported 12 melanoma cases among 89 long-term users, but without a matched control group and histological analysis of the tumours, it's impossible to separate Melanotan-2 effect from background risk

The SURMOUNT-2 trial (2023) focused specifically on patients with type 2 diabetes and obesity, demonstrating average weight loss of 14.7% at the 15 mg dose, a substantial improvement over prior GLP-1 monotherapy results in this population

Separately, Sun et al

Move away from the shower stream

This avoids the need to perform aseptic technique in non-ideal travel conditions

While traditional weight loss methods remain important, AOD-9604 offers a complementary approach that addresses the biochemical and metabolic aspects of weight gain